All In Biotech

NDA 021024 · Sanofi Aventis US

Priftin

Rifapentine · Oral · Rifamycin Antimycobacterial

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jun 22, 1998

Approved uses

4

Original approval plus efficacy supplements

Registered trials

68

25 Phase 3, 10 recruiting

FAERS reports

526

379 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 6, 2026.

PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. ( 1.1 ) PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. tuberculosis in combination with isoniazid in patients 2 years of age and older at high risk of progression to TB disease. ( 1.2 ) See Full Prescribing Information for Limitations of Use. ( 1.1 , 1.2 ) 1.1 Active Pulmonary Tuberculosis PRIFTIN ® (rifapentine) is indicated in adults and pediatric patients 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis . PRIFTIN must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . Limitations of Use Do not use PRIFTIN monotherapy in either the initial or the continuation phases of active antituberculous treatment. PRIFTIN should not be used once weekly in the continuation phase regimen in combination with isoniazid (INH) in HIV-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (RIF)-resistant organisms [see Warnings and Precautions (5.4) and Clinical Studies (14.1) ] . PRIFTIN has not been studied as part of the initial phase treatment regimen in HIV-infected patients with active pulmonary tuberculosis. 1.2 Latent Tuberculosis Infection PRIFTIN is indicated in adults and pediatric patients 2 years and older for the treatment of latent tuberculosis infection caused by Mycobacterium...

Mechanism: Rifapentine, a cyclopentyl rifamycin, is an antimycobacterial agent [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PRIFTIN · RIFAPENTINE 150MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Rifapentine" as an intervention, any sponsor and status, largest first.

All 68 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction67
  • pyrexia66
  • nausea52
  • fatigue48
  • vomiting44
  • hypertension40
  • off label use40
  • headache32
  • rash32
  • dizziness31
  • dyspnoea31
  • influenza like illness27

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20073
20101
20111
20128
201315
201416
201520
201610
201773
201860
201950
202019
202158
202229
202313
202432
202573
202645

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Resolved · updated Aug 6, 2026

    Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Priftin (Rifapentine)

2024 spending

$552K

Beneficiaries

1,697

2,888 claims

Per beneficiary

$325

$4.79 per unit

View as table
YearSpending
2020$227,358
2021$296,715
2022$280,673
2023$420,148
2024$551,921

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 140 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.